PTK2B and melanoma: Thus, our study also provided a potential treatment strategy, i.e., a combination of PYK2 inhibitor PF562271 with the BRAF inhibitor, vemurafenib, that may be an effective therapy to prolong the survival of patients with vemurafenib resistant melanomas.